Skip to main contentAI and Advanced
/
BAFNAPH · BSEMarket ticker unavailable · configure an authorised index feed
BA
BSE · Equity shares · Biotechnology & Drugs4.65 · 2.00%
Bafna Pharmaceuticals BAFNAPH
NSE:INR 238.25
BSE:INR 237.65
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceStale · last-known data
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for BAFNAPH
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 233
Day rangeINR 238.25 — INR 238.25
52-week rangeINR 77.01 — INR 234.15
Volume3,649
Market cap562.19
P/E23.03
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)150.62
Net Income (INR Cr)11.1
Rev Growth (5 Year %)16.16
EPS Growth (5 Year %)13.78
P/E Ratio23.03
Book Value40.64
EPS4.69
Price/BV5.85Computed
Research path: Interpret Bafna Pharmaceuticals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
BAFNAPHBafna Pharmaceuticals1d · INR · BSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 175.53 | 153.08 | 147.68 |
| Cash Equivalents | 2.02 | 3.43 | 1.4 |
| Other Liabilities Total | 4.41 | 2.39 | 2.01 |
| Long Term Debt | 17.78 | 14.03 | 10.75 |
| Common Stock Total | 23.66 | 23.66 | 23.66 |
| Other Current Assets Total | 12.9 | -0.8 | Not available |
| Total Assets | 175.53 | 153.08 | 147.68 |
| Current Portof LT Debt/Capital Leases | 19.65 | 5.6 | 3.62 |
| Total Equity | 96.15 | 84.81 | 80.84 |
| Long Term Investments | 0.96 | 0 | 0.7 |
| Retained Earnings(Accumulated Deficit) | 72.49 | -14.23 | -18.19 |
| Total Common Shares Outstanding | 2.37 | 2.37 | 2.37 |
| Tangible Book Valueper Share Common Eq | 40.64 | 35.85 | 33.42 |
| Total Liabilities | 79.38 | 68.27 | 66.84 |
| Total Debt | 37.43 | 28.2 | 24.39 |
| Short Term Investments | 1.71 | 0 | 0 |
| Cashand Short Term Investments | 3.74 | 3.43 | 1.4 |
| Total Receivables Net | 44.11 | 52.13 | 61.51 |
| Accounts Receivable-Trade Net | 43.93 | 40.17 | 45.39 |
| Property/Plant/Equipment Total-Net | 84.92 | 66.09 | 50.71 |
| Total Current Liabilities | 57.19 | 51.85 | 54.08 |
| Total Inventory | 28.9 | 29.44 | 30.4 |
| Accounts Payable | 31.29 | 30.95 | 35.42 |
| Other Currentliabilities Total | 6.25 | 6.66 | 4.94 |
| Total Long Term Debt | 17.78 | 14.03 | 10.75 |
| Other Long Term Assets Total | 0 | 2.26 | 0.73 |
| Total Current Assets | 89.65 | 84.73 | 93.77 |
| Accumulated Depreciation Total | Not available | -46.75 | -59.28 |
| Accrued Expenses | Not available | 0.08 | 0.09 |
| Prepaid Expenses | Not available | 0.52 | 0.46 |
| Additional Paid-In Capital | Not available | 75.38 | 75.38 |
| Property/Plant/Equipment Total-Gross | Not available | 105.53 | 99.49 |
| Notes Payable/Short Term Debt | Not available | 8.57 | 10.01 |
| Intangibles Net | Not available | Not available | 1.77 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %18.85
Margins
Operating Margin 12m6.56
Operating Margin 5y Avg5.96
Net Profit Margin 12m7.37
Net Profit Margin 5y6.03
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio3.73
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk60.24
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,939.15 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,370 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,985.5 | 1.69 L | 72.73 | — |
| Cipla | INR 1,410.1 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,121 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 75.00%
- FII
- 9.34%
- Other
- 15.66%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent - Markets MojoMarket news · 4 Jun 2026, 10:21 am
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent Markets Mojo
Above All Moving Averages and Now at Upper Circuit: Bafna Pharmaceuticals Ltd Gains 5.0% in a Single Session - Markets MojoMarket news · 3 Jun 2026, 10:34 am
Above All Moving Averages and Now at Upper Circuit: Bafna Pharmaceuticals Ltd Gains 5.0% in a Single Session Markets Mojo
Bafna Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Challenges - Markets MojoMarket news · 3 Jun 2026, 8:01 am
Bafna Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Challenges Markets Mojo
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent - Markets MojoMarket news · 2 Jun 2026, 10:01 am
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent Markets Mojo
Bafna Pharmaceuticals FY26 net profit rises to ₹1,109.98 lakh - scanx.tradeMarket news · 1 Jun 2026, 12:30 pm
Bafna Pharmaceuticals FY26 net profit rises to ₹1,109.98 lakh scanx.trade
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5.09% Gain — Buyers Queue, Sellers Absent - Markets MojoMarket news · 1 Jun 2026, 10:32 am
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5.09% Gain — Buyers Queue, Sellers Absent Markets Mojo
Corporate actions
Events
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Bafna Pharmaceuticals
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Bafna Pharmaceuticals Limited is an India-based company, which is engaged in manufacturing of pharmaceutical formulations. The Company exports its products to the Europe, the United Kingdom, Australia, Sri Lanka, Africa, and Commonwealth countries.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- BAFNAPH
- BSE Code
- 532989
Questions
Stock FAQ
What is the symbol and ISIN of Bafna Pharmaceuticals?
Bafna Pharmaceuticals has the symbol BAFNAPH and ISIN - INE878I01022.
What is the current price of Bafna Pharmaceuticals?
Bafna Pharmaceuticals is currently trading at INR 237.65.
What are the year high and year low of Bafna Pharmaceuticals?
Bafna Pharmaceuticals has a year high of INR 234.15 and a year low of INR 77.01.
What is the market capitalization of Bafna Pharmaceuticals?
Bafna Pharmaceuticals has a market capitalization of INR 562.19 crore.
What is the P/E ratio of Bafna Pharmaceuticals?
Bafna Pharmaceuticals has a P/E ratio of 23.03.
What is the dividend yield of Bafna Pharmaceuticals?
Bafna Pharmaceuticals has a dividend yield of 0.00%.
How is the financial performance of Bafna Pharmaceuticals based on revenue, net income, and EPS?
Bafna Pharmaceuticals has revenue of INR 150.62 crore, net income of INR 11.10 crore, and EPS of INR 4.69.
What is the book value of Bafna Pharmaceuticals?
Bafna Pharmaceuticals has a book value of INR 40.64.
What is the debt-to-equity ratio of Bafna Pharmaceuticals?
Bafna Pharmaceuticals has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Bafna Pharmaceuticals?
Bafna Pharmaceuticals has a price-to-book ratio of 5.85 and a price-to-sales ratio of 3.73.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.